SPATA25

Across TCGA pan-cancer cohorts, SPATA25 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SPATA25 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPATA25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA25 expression acts as an unfavorable survival marker.

HNSC and ESCA are the cancer types where SPATA25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.098	0.746	<.001	24	view →
ESCA	DFS	Median	II,III,IV	0.089	0.522	.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SPATA25–HNSC (OS)

Open the HNSC breakdown →